Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: A randomized trial

Vaccine

Volumn 29, Issue 50, 2011, Pages 9376-9384

  Aichinger, Gerald ^a   Ehrlich, Hartmut J ^a   Aaskov, John G ^b,c   Fritsch, Sandor ^a   Thomasser, Christiane ^a   Draxler, Wolfgang ^a   Wolzt, Michael ^d   Müller, Markus ^d   Pinl, Fritz ^e   Van Damme, Pierre ^f   Hens, Annick ^f   Levy, Jack ^g   Portsmouth, Daniel ^a   Holzer, Georg ^a   Kistner, Otfried ^a   Kreil, Thomas R ^a   Barrett, P Noel ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e Sanatorium Leech   (Austria)

^f UNIVERSITY OF ANTWERP   (Belgium)

^g Clinical Investigation Unit   (Belgium)

Author keywords

Clinical trial; Epidemic polyarthritis; Ross River virus; Ross River virus vaccine; RRV; Vero cell culture derived vaccine

Indexed keywords

IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; ROSS RIVER ALPHA VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; AUSTRIA; BELGIUM; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; HEADACHE; HEMATOMA; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE TENDERNESS; LYMPHADENOPATHY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NETHERLANDS; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROSS RIVER ALPHA VIRUS; VERO CELL; VIRUS INACTIVATION; VIRUS NEUTRALIZATION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALPHAVIRUS INFECTIONS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; AUSTRIA; BELGIUM; CERCOPITHECUS AETHIOPS; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MALE; NETHERLANDS; NEUTRALIZATION TESTS; ROSS RIVER VIRUS; VACCINES, INACTIVATED; VERO CELLS; VIRAL VACCINES; YOUNG ADULT;

EID: 80855131565     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.125     Document Type: Article

References (33)

1. Aaskov J. Ross River virus: epidemic polyarthritis. Vaccines for biodefense and emerging and neglected diseases 2009, 631-644. Elsevier, London. A.D.T. Barrett, L.R. Stanberry (Eds.).
2. Harley D., Sleigh A., Ritchie S. Ross River virus transmission, infection, and disease: a cross-disciplinary review. Clin Microbiol Rev 2001, 14:909-932.
3. Australian Government National Notifiable Diseases Surveillance System. Number of notifications of Ross River virus infection, received from State and Territory health authorities in the period of 1991 to 2010 and year-to-date notifications for 2011.Australian Government National Notifiable Diseases Surveillance System, available from: [accessed 26.09.2011]. http://www9.health.gov.au/cda/source/Rpt_4_sel.cfm.
4. Barber B., Denholm J.T., Spelman D. Ross River virus. Aust Fam Physician 2009, 38:586-589.
5. Jacups S.P., Whelan P.I., Currie B.J. Ross River virus and Barmah Forest virus infections: a review of history, ecology, and predictive models, with implications for tropical northern Australia. Vector Borne Zoonotic Dis 2008, 8:283-297.
6. Holzer G.W., Coulibaly S., Aichinger G., Savidis-Dacho H., Mayrhofer J., Brunner S., et al. Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection. Vaccine 2011, 29:4132-4141.
7. Kistner O., Barrett N., Bruhmann A., Reiter M., Mundt W., Savidis-Dacho H., et al. The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans. Vaccine 2007, 25:4845-4852.
8. Ehrlich H.J., Pavlova B.G., Fritsch S., Poellabauer E.M., Loew-Baselli A., Obermann-Slupetzky O., et al. Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity. Vaccine 2003, 22:217-223.
9. Tauber E., Kollaritsch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007, 370:1847-1853.
10. Wichmann B.A., Hill I.D. Algorithm 183. An efficient and portable pseudo-random number generator. Appl Stat 1982, 31:188-190.
11. Mcleod A. Remark AS R58. A remark on algorithm AS 183. An efficient and portable pseudo-random number generator. Appl Stat 1985, 121:811-822.
12. Yu S., Aaskov J.G. Development of a candidate vaccine against Ross River virus infection. Vaccine 1994, 12:1118-1124.
13. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938, 27:493-497.
14. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008, 358:2573-2584.
15. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
16. Stephenson I., Nicholson K.G., Gluck R., Mischler R., Newman R.W., Palache A.M., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003, 362:1959-1966.
17. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357:1937-1943.
18. DeMeio J.L., DeSanctis A.N., Thomas W.J. Persistence in humans of antibody after immunization with four alphavirus vaccines. Asian J Infect Dis 1979, 3:119-124.
19. Edelman R., Ascher M.S., Oster C.N., Ramsburg H.H., Cole F.E., Eddy G.A. Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84). J Infect Dis 1979, 140:708-715.
20. Edelman R., Tacket C.O., Wasserman S.S., Bodison S.A., Perry J.G., Mangiafico J.A. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 2000, 62:681-685.
21. Engler R.J., Mangiafico J.A., Jahrling P., Ksiazek T.G., Pedrotti-Krueger M., Peters C.J. Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine. J Med Virol 1992, 38:305-310.
22. Pittman P.R., Makuch R.S., Mangiafico J.A., Cannon T.L., Gibbs P.H., Peters C.J. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 1996, 14:337-343.
23. Steele K.E., Reed D.S., Glass P.J., Hart M.K., Ludwig G.V., Pratt W.D., et al. Alphavirus encephalitides. Medical aspects of biological warfare 2007, 241-270. Office of the Surgeon General, US Army Medical Department Center and School, Borden Institute, Washington, DC. Z.F. Dembek (Ed.).
24. Heinz F.X., Holzmann H., Essl A., Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 2007, 25:7559-7567.
25. Dubischar-Kastner K., Eder S., Buerger V., Gartner-Woelfl G., Kaltenboeck A., Schuller E., et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine 2010, 28:5197-5202.
26. Monath T.P., Fowler E., Johnson C.T., Balser J., Morin M.J., Sisti M., et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med 2011, 364:1326-1333.
27. Durbin A.P., Whitehead S.S. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 2010, 338:129-143.
28. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28:632-649.
29. Halstead S.B., Thomas S.J. Japanese encephalitis: new options for active immunization. Clin Infect Dis 2010, 50:1155-1164.
30. McClain D.J., Pittman P.R., Ramsburg H.H., Nelson G.O., Rossi C.A., Mangiafico J.A., et al. Immunologic interference from sequential administration of live attenuated alphavirus vaccines. J Infect Dis 1998, 177:634-641.
31. Pittman P.R., Liu C.T., Cannon T.L., Mangiafico J.A., Gibbs P.H. Immune interference after sequential alphavirus vaccine vaccinations. Vaccine 2009, 27:4879-4882.
32. Seligman S.J., Gould E.A. Live flavivirus vaccines: reasons for caution. Lancet 2004, 363:2073-2075.
33. Seligman S.J., Gould E.A. Safety concerns with regard to live attenuated flavivirus vaccines. J Infect Dis 2008, 198:794-795.